Travere Therapeutics (TVTX) EBT (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of EBT data on file, last reported at -$36.7 million in Q1 2026.

• Quarterly EBT rose 10.84% year-over-year to -$36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.8 million (up 80.17% YoY) and the FY2025 annual result came in at -$49.3 million, up 84.63% from the prior year.
• EBT retreated to -$36.7 million in Q1 2026, from -$21.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $25.7 million in Q3 2025 to a low of -$135.8 million in Q1 2024.
• A 5-year average of -$65.5 million and a median of -$80.0 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT tumbled 135.75% — and 2025, when it jumped 146.89%.
• Tracing TVTX's EBT over 5 years: stood at -$85.6 million in 2022, then retreated by 3.45% to -$88.5 million in 2023, then soared by 31.84% to -$60.3 million in 2024, then surged by 65.09% to -$21.1 million in 2025, then tumbled by 74.33% to -$36.7 million in 2026.
• The last three EBT figures came in at -$36.7 million (Q1 2026), -$21.1 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.